Vertex Pharmaceuticals Inc. closed 5.66% below its 52-week high of $519.88, which the company reached on November 8th.

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.37% to $477.52 Monday, on what proved to be an all-around dismal trading ...